Understanding the role of UBQLN2 in ALS and frontotemporal dementia
Official title: Investigation of UBQLN2 in neuronal dysfunction and ALS-FTD
Funded at University of Colorado · NIH-11098689 · Data updated 2026-11-12
This study is looking at how changes in the UBQLN2 gene might cause problems in the brain for people with ALS-FTD, with the hope of finding new ways to help treat those affected by this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project start | June 15, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $650,937 |
| NIH project number | 5R01NS131660-03 |
| Project ID | NIH-11098689 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with ALS-FTD, particularly those with a familial history of the disease.
✕Less likely to help
Patients with other forms of neurodegenerative diseases unrelated to ALS-FTD may not benefit from this research.
What this research studies
This research investigates the role of the UBQLN2 gene in the neurodegenerative disease known as Amyotrophic Lateral Sclerosis with frontotemporal dementia (ALS-FTD). The study aims to uncover the mechanisms by which mutations in UBQLN2 contribute to the disease, focusing on how it affects the degradation of problematic proteins in neurons. By examining both familial and sporadic cases of ALS-FTD, the research seeks to identify potential therapeutic targets that could lead to effective treatments for patients suffering from this condition.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life and longevity for patients with ALS-FTD.
How similar studies have gone: Previous research has shown promise in understanding the genetic factors contributing to ALS-FTD, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Colorado
Boulder, United States Active
Researchers
- Principal investigator: Whiteley, Alexandra — University of Colorado
- Study coordinator: Whiteley, Alexandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.